Retroviral vector-mediated transfer of the interferon-α gene in chronic myeloid leukemia cells

Cancer Gene Therapy

Volumn 5, Issue 6, 1998, Pages 390-400

  Salesse, Stéphanie ^a   Moreau Gaudry, François ^a   Pigeonnier Lagarde, Valérie ^a   Mazurier, Frédéric ^a   Chahine, Hikmat ^a   Ged, Cécile ^a   De Verneuil, Hubert ^a   Reifiers, Josy ^a   Mahon, François Xavier ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chronic myelogenous leukemia; Gene therapy; Interferon ; Retroviral gene transfer

Indexed keywords

ALPHA INTERFERON; CD34 ANTIGEN;

ANIMAL; ARTICLE; CELL DIVISION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; FETUS BLOOD; FLOW CYTOMETRY; GENE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; RETROVIRUS; TIME;

ANIMALS; ANTIGENS, CD34; CELL DIVISION; FETAL BLOOD; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, MHC CLASS I; GENETIC VECTORS; HUMANS; INTERFERON-ALPHA; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; MICE; RETROVIRIDAE; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 0032197332     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132: 1497-1500.
2. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to granulocyte, platelet, and monocyte/macrophage. Am J Med. 1977;63:125-130.
3. de Klein A, Geurts van Kessel A, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300:765-770.
4. Shtivelman E, Lifshitz B, Gale RP, Cananii E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature. 1985;315:550-554.
5. Guo JQ, Wang JYJ, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res. 1991;51:3048-3056.
6. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myeloid leukemia in mice by P210 bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
7. Goldman JM, Apperley JF, Jones LM, Marcus RE, Goolden AWG, Batchelor JR, Hale G, Waldmann H, Rei CD, Hows JM, Gordon-Smith EC, Catowsky D, Galton DAG. Bone marrow transplantation for patients with chronic myeloid leukemia. New Engl J Med. 1986;314:202-207.
8. McGlave PB, De Fabritiis P, Deisseroth J, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D. Autologous transplants for chronic myelogenous leukemia: results from eight transplant groups. Lancet. 1994; 343:1486-1488.
9. Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JV. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114:532-538.
10. The Italian cooperative study group on chronic myeloid leukemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
11. Allan NC, Richard SM, Shepherd PCA. U.K. Medical Research Council randomised, multicentre trial of interferon-α n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response: the U.K. Medical Research Council's working parties for therapeutic trials in adult leukemia. Lancet. 1995;345:1392-1397.
12. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia following cytogenetic response to interferon-a therapy. Ann Intern Med. 1995;122:254-261.
13. Gansbachcr B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, Gilboa E, Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood. 1992;80:2817-2825.
14. Kühr T, Dougherty GJ, Klingemann HG. Transfer of the tumor necrosis factor alpha gene into hematopoietic progenitor cells as a model for site-specific cytokine delivery after marrow transplantation. Blood. 1994;84:2966-2970.
15. Mace K, Seif I, Anjard C, Demaeyer-Guignard J, Duc-Dodon M, Gazzolo L, De Maeyer E. Enhanced resistance to HIV-1 replication in U937 cells stably transfected with the human IFN-β gene behind a MHC promoter fragment. J Immunol. 1991;147:3553-3559.
16. Ogura H, Tani K, Ozawa K, Nagata S, Asano S, Takaku F. Implantation of genetically manipulated fibroblasts into mice as antitumor α-interferon therapy. Cancer Res. 1990; 50:5102-5106.
17. Belldegrun A, Tso CL, Sakata T, Duckett T, Brunda MJ, Barsky SH, Chai J, Kaboo R, Lavey RS, McBride WH. Human renal carcinoma line transfected with interleukin-2 and/or interferon-α gene(s): implication for live cancer vaccines. J Natl Cancer Inst. 1993;85:207-216.
18. + T cell-mediated tumor rejection and development of antitumor immunity: comparative studies with IFN-γ-producing TS/A cells. J Immunol. 1994:4604-4615.
19. Santodonato L, Ferrantini M, Gabriele L, Proietti E, Venditti M, Musiani P, Modesti A, Modica A, Lupton SD, Belardelli F. Cure of mice with established metastatic Friend leukemia cell tumor by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther. 1996;7:1-10.
20. Miller AD, Rossman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-989.
21. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460-6464.
22. Danos O. Construction of retroviral packaging cell lines. Methods Mol Biol. 1991;8:17-27.
23. Sarkar S, Flores I, De Rosa C, Ozzello L, Ron Y, Pestka S. Injection of irradiated B16 melanoma genetically modified to secrete IFN-α causes regression of an established tumor. Int J Oncol. 1995;7:17-24.
24. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, and White DE. Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989;7:1863-1874.
25. Raefsky EL, Platanias LC, Zoumbos NC, Young NS. Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol. 1985;135:2507-2512.
26. Carlo-Stella C, Cazzola M, Ganser A, Bergamaschi G, Pedrazzoli P, Hoelzer D, Ascari E. Synergistic antiproliferative effect of recombinant interferon-γ with recombinant interferon-α on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). Blood. 1988;72:1293-1299.
27. Galvani DW, Cawley JC. Mechanism of action of α interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br J Haematol 1989;73:475-479.
28. Gronthos S, To LB, Haylock DN, Juttner CA. A differential sensitivity to recombinant human interferon-alpha 2a between normal and chronic myeloid leukemic peripheral blood granulocyte-macrophage colony-forming units. Leuk Res. 1992;16:153-158.
29. Dowding C, Guo AP, Maisin D, Gordon MY, Goldman JM. The effects of interferon-alpha on the proliferation of CML progenitors cells in vitro are not related to the precise position of the M-BCR breakpoint. Br J Haematol. 1991;77:165-172.
30. Després D, Goldschmitt J, Aulitzky WE, Huber C, Peschel C. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors. Exp Hematol. 1995;23:1431-1438.
31. Kotani H, Newton PB, III, Zhang S, Chiang YL, Otto E, Weaver L, Blaese RM, Anderson WF, McGarrity GJ. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther. 1994;5:19-28.
32. Bahnson AB, Dunigan JT, Baysal BE, Mohney T, Atchison RW, Nimgaonkar MT, Ball ED, Barranger JA. Centrifugal enhancement of retroviral-mediated gene transfer. J Virol Methods. 1995;54:131-143.
33. Cornetta K, Moore A, Leemhuis T, Moen RC, Tricot G, Leibowilz D, Hoffman R. Retroviral-medialed gene transfer in chronic myelogenous leukaemia. Br J Haematol. 1994;87:308-316.
34. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-α reslores normal β1-integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood. 1996; 87:3883-3891.
35. Gresser I, Carnaud C, Maury C. Host humoral and cellular immune mechanism in the continued suppression of Friend erythroleukemia metastases after interferon αβ treatment in mice. J Exp Med. 1991;173:1193-1203.
36. Sirard C, Lapidot T, Vormoor J, Cashman JD, Doedens M, Murdoch B, Jamal N, Messner H, Addey L, Minden M, Laraya P, Keating A, Eaves A, Lansdorp PM, Eaves CJ, Dick JE. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood. 1996;87:1539-1548.
37. Holtschke T, Löhler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobeloch K-P, Gabriele L, Waring JF, Bachmann F, Zinkernagel RM, Morse HC, III, Ozato K, Horak I. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-317.